{"id":869799,"date":"2025-07-15T10:21:52","date_gmt":"2025-07-15T14:21:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/"},"modified":"2025-07-15T10:21:52","modified_gmt":"2025-07-15T14:21:52","slug":"investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/","title":{"rendered":"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action &#8211; SRPT"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 15, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Levi &amp; Korsinsky, LLP notifies investors in <b>Sarepta Therapeutics, Inc.<\/b> (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) of a class action securities lawsuit.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" title=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" alt=\"Levi &amp; Korsinsky, LLP (PRNewsfoto\/Levi &amp; Korsinsky, LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b>CLASS DEFINITION: <\/b>The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by <span>alleged<\/span> securities <span>fraud<\/span> between <span class=\"xn-chron\">June 22, 2023<\/span> and <span class=\"xn-chron\">June 24, 2025<\/span>. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n<p>\n        <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4468017-12&amp;h=986554737&amp;u=https%3A%2F%2Fzlk.com%2Fpslra-1%2Fsarepta-lawsuit-submission-form%3Fprid%3D156575%26wire%3D4&amp;a=https%3A%2F%2Fzlk.com%2Fpslra-1%2Fsarepta-lawsuit-submission-form%3Fprid%3D156575%26wire%3D4\" target=\"_blank\" rel=\"nofollow\">https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=156575&amp;wire=4<\/a>\u00a0<\/p>\n<p>\n        <b>SRPT<\/b>\u00a0investors may also contact <span class=\"xn-person\">Joseph E. Levi, Esq.<\/span> via email <a href=\"mailto:at\u00a0jlevi@levikorsinsky.com\u00a0or\" rel=\"nofollow\">at\u00a0jlevi@levikorsinsky.com\u00a0or<\/a> by telephone at (212) 363-7500.<\/p>\n<p>\n        <b>CASE DETAILS: <\/b>The filed complaint <span>alleges<\/span> that defendants made false statements and\/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy&#8217;s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and\/or lacked a reasonable basis for, their positive statements.<\/p>\n<p>\n        <b>WHAT&#8217;S NEXT? <\/b>If you suffered a loss in Sarepta during the relevant time frame, you have until <b><span class=\"xn-chron\">August 25, 2025<\/span><\/b>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn&#8217;t require that you serve as a lead plaintiff.<\/p>\n<p>\n        <b>NO COST TO YOU: <\/b>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. <b>There is no cost or obligation to participate.<\/b><\/p>\n<p>\n        <b>WHY LEVI &amp; KORSINSKY: <\/b>Over the past 20 years, the team at Levi &amp; Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services&#8217; Top 50 Report as one of the top securities litigation firms in <span class=\"xn-location\">the United States<\/span>.<\/p>\n<p>\n        <b>CONTACT:<\/b><br \/>\n        <br \/>Levi &amp; Korsinsky, LLP <br \/><span class=\"xn-person\">Joseph E. Levi, Esq.<\/span><br \/><span class=\"xn-person\">Ed Korsinsky, Esq.<\/span><br \/>33 Whitehall Street, 17th Floor<br \/><span class=\"xn-location\">New York, NY<\/span> 10004<br \/><a href=\"mailto:jlevi@levikorsinsky.com\" rel=\"nofollow\">jlevi@levikorsinsky.com<\/a><br \/>Tel: (212) 363-7500<br \/>Fax: (212) 363-7171<br \/><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4468017-12&amp;h=762884548&amp;u=https%3A%2F%2Fwww.zlk.com%2F&amp;a=www.zlk.com\" target=\"_blank\" rel=\"nofollow\">www.zlk.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY30015&amp;sd=2025-07-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/investors-who-lost-money-on-sarepta-therapeutics-incsrpt-should-contact-levi--korsinsky-about-pending-class-action---srpt-302505064.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/investors-who-lost-money-on-sarepta-therapeutics-incsrpt-should-contact-levi&#8211;korsinsky-about-pending-class-action&#8212;srpt-302505064.html<\/a><\/p>\n<p>SOURCE  Levi &amp; Korsinsky, LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY30015&amp;Transmission_Id=202507150900PR_NEWS_USPR_____NY30015&amp;DateId=20250715\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , July 15, 2025 \/PRNewswire\/ &#8212;\u00a0Levi &amp; Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=156575&amp;wire=4\u00a0 SRPT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action &#8211; SRPT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-869799","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action - SRPT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action - SRPT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , July 15, 2025 \/PRNewswire\/ &#8212;\u00a0Levi &amp; Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=156575&amp;wire=4\u00a0 SRPT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks &hellip; Continue reading &quot;Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action &#8211; SRPT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T14:21:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action &#8211; SRPT\",\"datePublished\":\"2025-07-15T14:21:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/\"},\"wordCount\":425,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/\",\"name\":\"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action - SRPT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"datePublished\":\"2025-07-15T14:21:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280334\\\/Levi_and_Korsinsky_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action &#8211; SRPT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action - SRPT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/","og_locale":"en_US","og_type":"article","og_title":"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action - SRPT - Market Newsdesk","og_description":"PR Newswire NEW YORK , July 15, 2025 \/PRNewswire\/ &#8212;\u00a0Levi &amp; Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221; or the &#8220;Company&#8221;) (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/sarepta-lawsuit-submission-form?prid=156575&amp;wire=4\u00a0 SRPT\u00a0investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks &hellip; Continue reading \"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action &#8211; SRPT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-15T14:21:52+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action &#8211; SRPT","datePublished":"2025-07-15T14:21:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/"},"wordCount":425,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/","name":"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action - SRPT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","datePublished":"2025-07-15T14:21:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280334\/Levi_and_Korsinsky_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-sarepta-therapeutics-inc-srpt-should-contact-levi-korsinsky-about-pending-class-action-srpt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investors who lost money on Sarepta Therapeutics, Inc.(SRPT) should contact Levi &amp; Korsinsky about pending Class Action &#8211; SRPT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=869799"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869799\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=869799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=869799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=869799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}